- Abbott India‘s net income for the first quarter was 3.66 billion rupees, a 12% increase from the previous year.
- Despite the increase, net income missed market estimates, which were pegged at 3.78 billion rupees.
- The company reported revenues of 17.4 billion rupees, which is also a 12% increase from the previous year, surpassing the estimated revenue of 17.04 billion rupees.
- Total costs for the first quarter rose to 13.2 billion rupees, marking an 11% increase compared to the previous year.
- Market analysts are generally optimistic about Abbott India, with 7 buy recommendations, 0 hold recommendations, and 1 sell recommendation reported.
“`
A look at Abbott India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott India Limited, a company manufacturing pharmaceuticals, medical products, agrochemicals, and animal health products, seems to have a promising long-term outlook based on its Smartkarma Smart Scores. Despite scoring moderately on the value factor with a 2 rating, the company excels in providing dividends with a top-notch score of 5. Additionally, Abbott India demonstrates strong growth potential with a score of 4, indicating positive prospects for increasing revenue and market share. The company’s resilience score of 5 suggests a sturdy ability to weather economic fluctuations, while its momentum score of 4 showcases a favorable trend in performance.
Overall, Abbott India appears well-positioned for continued success in the industry, leveraging its strengths in dividend distribution, growth opportunities, resilience, and positive momentum. With a diverse product portfolio including insulin injections, anti-dysentery drugs, and household remedies, Abbott India‘s focus on delivering value to its stakeholders while maintaining steady growth bodes well for its outlook in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
